$DYAI
DYADIC INTERNATIONAL INC Stock $dyai

$dyai Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000143774922012148 Filed on May 12, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q1
Revenue	$658.6K	$648.4M	$460.5M
YoY Change	-29.72%	40.8%	145924.38%
Cost Of Revenue	$411.1K	$404.7M	$390.8M
YoY Change	-50.44%	3.58%	140369.91%
Gross Profit	$247.4K	$243.7M	$69.76M
YoY Change	129.99%	249.32%	187471.93%
Gross Profit Margin	37.57%	37.58%	15.15%
Selling, General & Admin	$1.714M	$1.656M	$1.550M
YoY Change	-1.92%	6.82%	-6.06%
% of Gross Profit	692.69%	0.68%	2.22%
Research & Development	$1.831M	$1.343B	$1.808B
YoY Change	-17.13%	-25.73%	239239.58%
% of Gross Profit	739.88%	551.07%	2591.96%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.831M	$1.343B	$1.808B
YoY Change	-17.13%	-25.73%	239239.58%
Operating Profit	-$3.318M	-$2.745B	-$3.321B
YoY Change	-14.2%	-17.35%	139274.12%
Interest Expense	$30.01K	$2.968M	$25.67M
YoY Change	43.58%	-88.44%	15145.01%
% of Operating Profit
Other Income/Expense, Net	$30.01K	$253.0M	$25.67M
YoY Change	43.58%	885.46%
Pretax Income	-$3.288M	-$2.492M	-$3.290M
YoY Change	-14.51%	-24.27%	48.87%
Income Tax
% Of Pretax Income
Net Earnings	-$3.288M	-$2.492M	-$3.295M
YoY Change	-14.51%	-24.38%	48.81%
Net Earnings / Revenue	-499.28%	-0.38%	-0.72%
Basic Earnings Per Share	-$0.12	-$0.09	-$0.12
Diluted Earnings Per Share	-$116.3K	-$88.20K	-$119.5K
COMMON SHARES
Basic Shares Outstanding	28.26M		27.55M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.64M	$15.44M	$27.23M
YoY Change	-38.91%	-43.3%	-12.95%
Cash & Equivalents	$9.476M	$12.42B	$13.06M
Short-Term Investments	$6.164M	$3.021M	$14.18M
Other Short-Term Assets	$104.8K	$244.2K	$220.0K
YoY Change	3.91%	10.99%	-24.14%
Inventory
Prepaid Expenses
Receivables	$1.145M	$528.2M	$385.0K
Other Receivables	$42.24K	$28.90K	$160.0K
Total Short-Term Assets	$16.93M	$16.24B	$27.99M
YoY Change	-35.26%	57922.59%	-14.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$284.7K	$2.283M	$280.0K
YoY Change	0.0%	715.3%	-88.89%
Other Assets	$6.024K	$6.104M	$6.151K
YoY Change	-2.4%	99135.9%	-87.82%
Total Long-Term Assets	$290.7K	$2.289B	$290.9K
YoY Change	-0.05%	786853.52%	-88.68%
TOTAL ASSETS
Total Short-Term Assets	$16.93M	$16.24B	$27.99M
Total Long-Term Assets	$290.7K	$2.289B	$290.9K
Total Assets	$17.22M	$18.53B	$28.28M
YoY Change	-34.88%	65419.07%	-20.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.095M	$866.3M	$1.474M
YoY Change	-55.02%	58680.93%	125.57%
Accrued Expenses	$1.224M	$533.0M	$277.7K
YoY Change	105.84%	191858.38%	15.69%
Deferred Revenue	$901.3K	$315.0M	$842.2K
YoY Change	248.34%	37300.62%	247.4%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.397M	$1.826B	$2.594M
YoY Change	3.31%	70319.08%	128.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$264.7K	$308.8K
YoY Change
Total Long-Term Liabilities	$264.7K	$308.8K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.397M	$1.826B	$2.594M
Total Long-Term Liabilities	$264.7K	$308.8K	$0.00
Total Liabilities	$3.662M	$2.135B	$2.590M
YoY Change	11.36%	82344.13%	127.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$69.53M	-$66.24B	-$53.97M
YoY Change	20.25%	122628.69%	23.89%
Common Stock	$40.52K	$40.52M	$39.81K
YoY Change	0.46%	101683.56%	0.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$18.93M	$18.93B	$18.90M
YoY Change	0.16%	100058.28%	0.0%
Treasury Stock Shares
Shareholders Equity	$13.56M	$16.39M	$25.69M
YoY Change
Total Liabilities & Shareholders Equity	$17.22M	$18.53B	$28.28M
YoY Change	-34.88%	65419.07%	-20.08%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$3.288M	-$2.492M	-$3.295M
YoY Change	-14.51%	-24.38%	48.81%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.775M	-$2.850B	-$1.907B
YoY Change	-25.96%	49.51%	95400.18%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$1.156M	-$520.9K	-$5.780M
YoY Change	-146.33%	-90.99%	-440.0%
Cash From Investing Activities	-$1.156M	-$520.9M	-$5.784B
YoY Change	-146.33%	-90.99%	-340809.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$42.35M	$115.8M
YoY Change	-100.0%	-63.43%	66071.43%
NET CHANGE
Cash From Operating Activities	-1.775M	-$2.850B	-$1.907B
Cash From Investing Activities	-1.156M	-$520.9M	-$5.784B
Cash From Financing Activities	0.000	$42.35M	$115.8M
Net Change In Cash	-2.932M	-$3.329B	-$7.581B
YoY Change	-404.0%	-56.08%	5983095.88%
FREE CASH FLOW
Cash From Operating Activities	-$1.775M	-$2.850B	-$1.907B
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28264157
CY2022Q1	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	1998120000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Noncurrent HeldToMaturitySecuritiesNoncurrent	0	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40517659
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40482659
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28264157
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28229157
CY2022Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2021Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	12253502
CY2022Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021	dyai	Deferred Tax Assets Valuation Allowance Coverage Percent DeferredTaxAssetsValuationAllowanceCoveragePercent	1	pure
CY2021	dyai	Research And Development Expense Related Party ResearchAndDevelopmentExpenseRelatedParty	0	USD
CY2017Q2	dyai	Collaborative Arrangement Payment For Research And Development Agreement CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement	1000000.0	EUR
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12419029000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15748480000	USD
CY2022Q1	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	3021064000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	4511780000	USD
CY2022Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	28894000	USD
CY2021Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	94375000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	528151000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	277831000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	244170000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	375830000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	16241308000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	21008296000	USD
CY2022Q1	dyai	Prepaid Research And Development In Process Current PrepaidResearchAndDevelopmentInProcessCurrent	284709000	USD
CY2021Q4	dyai	Prepaid Research And Development In Process Current PrepaidResearchAndDevelopmentInProcessCurrent	284709000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6104000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6117000	USD
CY2022Q1	us-gaap	Assets Assets	18530241000	USD
CY2021Q4	us-gaap	Assets Assets	21299122000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	866321000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1547953000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	533007000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	709560000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	315006000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	151147000	USD
CY2022Q1	dyai	Deferred License Revenue Current DeferredLicenseRevenueCurrent	112146000	USD
CY2021Q4	dyai	Deferred License Revenue Current DeferredLicenseRevenueCurrent	147059000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1826480000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2555719000	USD
CY2022Q1	dyai	Deferred License Revenue Net Of Current Portion DeferredLicenseRevenueNetOfCurrentPortion	308823000	USD
CY2021Q4	dyai	Deferred License Revenue Net Of Current Portion DeferredLicenseRevenueNetOfCurrentPortion	352941000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	2135303000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	2908660000	USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	40518000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	40483000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101522602000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	101026496000	USD
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	18929915000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	18929915000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66238267000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63746602000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	16394938000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18390462000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18530241000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21299122000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	648427000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	460520000	USD
CY2022Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	404746000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	390762000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1342862000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1808098000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1655700000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1554007000	USD
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	10248000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-28272000	USD
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	3393060000	USD
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	3781139000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2744633000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3320619000	USD
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	2968000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	25670000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	250000000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	252968000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	25670000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2491665000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3294949000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	28251324
CY2021Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	27533268
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18390462000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	453791000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42350000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2491665000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	16394938000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	28446561000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	421071000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115800000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3294949000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	25688483000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2491665000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-3294949000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	453791000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	421071000	USD
CY2022Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	13446000	USD
CY2021Q1	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	63951000	USD
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	10247000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-28272000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-65481000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	44954000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	241002000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	131800000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-131299000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-64297000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-679918000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	480455000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-176396000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-212088000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	163859000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	719232000	USD
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-79031000	USD
CY2021Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2850383000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1906513000	USD
CY2022Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	5020850000	USD
CY2021Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	11283940000	USD
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	4500000000	USD
CY2021Q1	us-gaap	Proceeds From Sale And Maturity Of Held To Maturity Securities ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities	5500000000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-520850000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5783940000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42350000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	115800000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42350000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	115800000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-568000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-6834000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3329451000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7581487000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15748480000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	20637045000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12419029000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	13055558000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p>
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For each of the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em>, the Company’s revenue was generate<span style="background-color:#ffffff;">d from <span style="-sec-ix-hidden:c84227426"><span style="-sec-ix-hidden:c84227427">eight</span></span> customers. As of </span><em style="font: inherit;"> March 31, 2022</em><span style="background-color:#ffffff;"> and </span><em style="font: inherit;"> December 31, 2021</em><span style="background-color:#ffffff;">, the Company’s accounts receivable was from <span style="-sec-ix-hidden:c84227428">six</span></span><span style="background-color:#ffffff;"> and <span style="-sec-ix-hidden:c84227429">eight</span> customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company’s customers could adversely affect its operations.</span></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the <em style="font: inherit;">three</em> months en<span style="background-color:#ffffff;">ded </span><em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em><span style="background-color:#ffffff;">, the Company had <span style="-sec-ix-hidden:c84227433">three</span> and <span style="-sec-ix-hidden:c84227434">six</span> customers outside of the United States (i.e., European and Asian customers) that accounted for approximately $136,000 or 25.5% and $353,000 or 76.6% of the revenue, respectively. </span></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> March 31, 2022</em>, the Company had <span style="-sec-ix-hidden:c84227439">three</span> customers outside of the United States (i.e., European and Asian customers) that accounted for approximately $244,000 or 46.2% of accounts receivable. As of <em style="font: inherit;"> December 31, 2021</em>, the Company had <span style="-sec-ix-hidden:c84227442">four</span> customers outside of the United States that accounted for approximately $157,000 or 56.4% of accounts receivable.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-indent: 36pt; text-align: justify;"><span style="background-color:#ffffff;">The Company uses several contract research organizations (“CROs”) to conduct its research projects. For the <em style="font: inherit;">three</em> months ended </span><em style="font: inherit;"> March 31, 2022 </em>and <em style="font: inherit;">2021</em><span style="background-color:#ffffff;">, <span style="-sec-ix-hidden:c84227447">two</span> and <span style="-sec-ix-hidden:c84227448">three</span> CROs accounted for approximately $1,494,000 or 96.7% and $2,017,000 or 98.1% of total research services we purchased, respectively. </span><span style="background-color:#ffffff;">As of </span><em style="font: inherit;"> March 31, 2022</em><span style="background-color:#ffffff;"> and </span><em style="font: inherit;"> December 31, 2021</em><span style="background-color:#ffffff;"> <span style="-sec-ix-hidden:c84227453"><span style="-sec-ix-hidden:c84227454">two</span></span> CROs accounted for approximately $731,000 or 84.4% and </span><span style="background-color:#ffffff;">approximately $1,312,000 or 84.8% of the accounts payable, respectively. The loss of <em style="font: inherit;">one</em> CRO or a combination of the Company’s CROs could adversely affect its operations.</span></p>
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2022Q1	us-gaap	Prepaid Insurance PrepaidInsurance	148734000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	326712000	USD
CY2022Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	86011000	USD
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	45839000	USD
CY2022Q1	dyai	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	8580000	USD
CY2021Q4	dyai	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	0	USD
CY2022Q1	us-gaap	Prepaid Taxes PrepaidTaxes	845000	USD
CY2021Q4	us-gaap	Prepaid Taxes PrepaidTaxes	3279000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	244170000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	375830000	USD
CY2022Q1	dyai	Research And Development In Process Current ResearchAndDevelopmentInProcessCurrent	765452000	USD
CY2021Q4	dyai	Research And Development In Process Current ResearchAndDevelopmentInProcessCurrent	1363889000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	66659000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	27675000	USD
CY2022Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	34210000	USD
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	156389000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	866321000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1547953000	USD
CY2022Q1	dyai	Accrued Research And Development In Process Current AccruedResearchAndDevelopmentInProcessCurrent	257000000	USD
CY2021Q4	dyai	Accrued Research And Development In Process Current AccruedResearchAndDevelopmentInProcessCurrent	194250000	USD
CY2022Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	200257000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	405758000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	75750000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	109552000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	533007000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	709560000	USD
CY2022Q1	dyai	Research And Development Expense Outside Contracted Services ResearchAndDevelopmentExpenseOutsideContractedServices	1135556000	USD
CY2021Q1	dyai	Research And Development Expense Outside Contracted Services ResearchAndDevelopmentExpenseOutsideContractedServices	1659194000	USD
CY2022Q1	dyai	Research And Development Expense Personnel Related Costs ResearchAndDevelopmentExpensePersonnelRelatedCosts	206790000	USD
CY2021Q1	dyai	Research And Development Expense Personnel Related Costs ResearchAndDevelopmentExpensePersonnelRelatedCosts	148162000	USD
CY2022Q1	dyai	Research And Development Expense Facilities Overhead And Other ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther	516000	USD
CY2021Q1	dyai	Research And Development Expense Facilities Overhead And Other ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther	742000	USD
CY2022Q1	dyai	Research And Development Expense Including Related Party ResearchAndDevelopmentExpenseIncludingRelatedParty	1342862000	USD
CY2021Q1	dyai	Research And Development Expense Including Related Party ResearchAndDevelopmentExpenseIncludingRelatedParty	1808098000	USD
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	14371386000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	15748480000	USD
CY2022Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	15200000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	13000000.0	USD
CY2022Q1	dyai	Deferred Tax Assets Valuation Allowance Coverage Percent DeferredTaxAssetsValuationAllowanceCoveragePercent	1	pure
CY2022Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	11332429000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	12419029000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12419029000	USD
CY2022Q1	dyai	Cash Cash Equivalents And Investments Fair Value CashCashEquivalentsAndInvestmentsFairValue	17420449000	USD
CY2022Q1	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	17764000	USD
CY2022Q1	us-gaap	Investments And Cash InvestmentsAndCash	17438213000	USD
CY2021Q4	us-gaap	Cash Cash	1377094000	USD
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5425040
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5324215
CY2022Q1	us-gaap	Cash Cash	1086600000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15748480000	USD
CY2021Q4	dyai	Cash Cash Equivalents And Investments Fair Value CashCashEquivalentsAndInvestmentsFairValue	20257765000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Accumulated Unrecognized Holding Loss HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss	2495000	USD
CY2021Q4	us-gaap	Investments And Cash InvestmentsAndCash	20260260000	USD
CY2021Q4	dyai	Upfront Payment Payable UpfrontPaymentPayable	500000	USD
CY2021Q4	dyai	Number Of Performance Obligations NumberOfPerformanceObligations	2	pure
CY2017Q2	dyai	Collaborative Arrangement Payment For Research And Development Agreement CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement	1100000	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3827242	USD
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M9D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.27
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M23D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3931706	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4070223
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.79
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.613	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4774215
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M20D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8413444	USD
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	715825
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.81
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	35000
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.21
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	30000
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.87
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5425040
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	453791	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	421071	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001

Files In Submission

Name	View Source	Status
0001437749-22-012148-index-headers.html	Edgar Link	pending
0001437749-22-012148-index.html	Edgar Link	pending
0001437749-22-012148.txt	Edgar Link	pending
0001437749-22-012148-xbrl.zip	Edgar Link	pending
dyai-20200930_g1copy.jpg	Edgar Link	pending
dyai-20220331.xsd	Edgar Link	pending
dyai-20220331_cal.xml	Edgar Link	unprocessable
dyai-20220331_def.xml	Edgar Link	unprocessable
dyai-20220331_lab.xml	Edgar Link	unprocessable
dyai-20220331_pre.xml	Edgar Link	unprocessable
dyai20220331_10q.htm	Edgar Link	pending
dyai20220331_10q_htm.xml	Edgar Link	completed
ex_342531.htm	Edgar Link	pending
ex_342532.htm	Edgar Link	pending
ex_342533.htm	Edgar Link	pending
ex_342534.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DYAI
DYADIC INTERNATIONAL INC Stock $dyai

2022 Q2 Form 10-Q Financial Statement

#000143774922012148 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DYAI DYADIC INTERNATIONAL INC Stock $dyai

2022 Q2 Form 10-Q Financial Statement

#000143774922012148 Filed on May 12, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DYAI
DYADIC INTERNATIONAL INC Stock $dyai